SEC Tracker
Get the app

Jade Biosciences JBIO

Jade Biosciences Appoints Brad Dahms as Chief Financial Officer

Form
8-K
Filed
Importance
Routine
  • Signs a material agreement (1.01)
  • Reports an executive or board change (5.02)
  • Makes a Regulation FD disclosure (7.01)

Not explained yet; the original is on EDGAR.

View on EDGAR

Open in the app

Get an email when Jade Biosciences files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Standard Biotools LAB public float $291M, Jun 30, 2025
  2. Aquestive Therapeutics AQST public float $292M, Jun 30, 2025
  3. Ocugen OCGN public float $279M, Jun 30, 2025
  4. Siga Technologies SIGA public float $302M, Jun 30, 2025
  5. Abeona Therapeutics ABEO public float $273M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.